The regulatory success of KRAS-targeting therapies marked a watershed moment, but there is room for improvement in the real world.

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic ...

Verastem, Inc. (NASDAQ:VSTM) Q4 2025 Earnings Call Transcript March 4, 2026 Verastem, Inc. misses on earnings expectations. Reported EPS is $-0.5 EPS, expectations were $-0.49. Operator: Good ...

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over ...

AstraZeneca’s latest update covers ALAFOSS-01, a first-in-human Phase I/IIa trial of AZD0022 in adults with advanced cancers carrying a KRASG12D mutation. The study aimed to test safety, dosing, and ...

Strengthened Executive Leadership. In February 2026, Foghorn appointed Ryan Maynard as Chief Financial Officer. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial ...

Detailed price information for Elicio Therapeutics Inc (ELTX-Q) from The Globe and Mail including charting and trades.

The firm received FDA feedback on the design of registrational studies of VS-7375, while it awaits new data for Avmapki Fakzynja.

Pancreatic cancer is one of the most dangerous forms of cancer in the world. It is known for being very difficult to detect and very hard to treat. I. n many cases, the disease gr ...

Pancreatic cancer is one of the most dangerous forms of cancer in the world. Doctors and scientists have struggled for many years to find effective treatments for it. Many patients are diagnosed at a ...